ITP News Briefs

Blood test

Complement Biomarkers Associated With Worse Treatment Response in ITP

Patients with primary immune thrombocytopenia (ITP) and high levels of complement biomarkers may have a worse response to treatment with thrombopoietin receptor agonists (TPO-RAs), according to a study published in Platelets. During the study, patients with primary ITP with significantly elevated baseline levels of soluble terminal complement complexes (sTCC) tended to have an inadequate platelet…

medication

The Role of Tyrosine Kinase Inhibitors in ITP Explored

Tyrosine kinase inhibitors could gain a leading role in the management of patients with immune thrombocytopenic purpura (ITP), according to an article recently published in the Journal of Xenobiotics. “In the early-phase clinical trial, rilzabrutinib oral (BTKI) was safe and well tolerated by most of the patients with ITP and was effective in patients with multidrug-resistant…

ITP life expectancy

Prognosis Appears to Be Improving for Primary Patients With ITP

Survival is reduced for patients with both primary and secondary immune thrombocytopenia (ITP) compared to the general population, according to a study published in Transfusion.  While survival was reduced for these patients, data seemed to show an improvement in the prognosis for patients with primary ITP over the years, the researchers noted. Secondary ITP, on…

Anxious man

Understanding the Impact of Immune Thrombocytopenia on Quality of Life

Immune thrombocytopenia is an autoimmune disorder characterized by isolated thrombocytopenia resulting from impaired platelet production and increased platelet destruction.  The chief goal of treatment is to stop any active bleeds and to prevent future ones from occurring. The main therapies used in this condition are corticosteroids and additional intravenous immunoglobulin in cases of active bleeding. …

medication

Cyclosporine Combination Therapy Effective in Treating ITP

The use of cyclosporine-based combination therapy is effective for treating primary immune thrombocytopenia (ITP), according to a meta-analysis published in the Journal of International Medical Research. In the analysis, cyclosporine-based combination therapy was found to increase platelet counts and improve overall response rate (ORR) and complete response (CR) rate in patients with ITP. Using pooled…

ITP history

Biosimilar Romiplostim Effectively Increases Platelet Count in Patients With ITP

Biosimilar romiplostim, launched in India by Intas Pharmaceuticals, was found to be effective in adult Indian patients with immune thrombocytopenia (ITP), according to a retrospective study published in the Indian Journal of Pathology & Microbiology. “Our study suggests that subcutaneous administration of biosimilar romiplostim was effective in increasing the platelet counts and well-tolerated in adult…

ITP life expectancy

Novel Study Will Assess Benefits of Herombopag in ITP

An upcoming study will evaluate the response to prolonged treatment with herombopag in patients with immune thrombocytopenia (ITP). Researchers will soon initiate the recruiting process for this phase 3 clinical trial. The study’s design is an interventional subtype with single group assignment and an open-label model. It expects to include an estimated 117 participants previously…

Clinical Trial

New ITP Trial Now Open 

A new phase 2 clinical trial testing an experimental antihuman CD38 monoclonal antibody for the treatment of immune thrombocytopenia (ITP) is now open. The prospective, 1-arm, open trial will assess the safety and efficacy of the experimental treatment called CM313 in an estimated 20 patients, who are at least 18 years of age and who…

data

Long-Term Survival May Be Reduced in ITP But Improvements Were Reported

Long-term survival is reduced in patients with chronic immune thrombocytopenia (ITP), according to a new population-based study published in the journal Transfusion. However, it seems to be improving compared to the past. The study also found that secondary ITP and comorbidities are associated with a poor prognosis. To investigate long-term survival in patients with primary…

Next post in ITP News Briefs